European Biotech Acquisition Operating Income

European Biotech Acquisition's operating income stands at $-2.8M as of December 2022. That compares with $-1.1M in the prior-year period — down 156.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

European Biotech Acquisition reported $-2.8M in operating income versus $-1.1M a year earlier — a 156.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-1.1M in the prior-year period — down 156.2% year over year. Sustained growth in operating income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how European Biotech Acquisition's operating income evolved across reporting periods, while the comparison chart places EBAC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.